Literature DB >> 23344600

Uncommon adverse effect of a common medication.

Kari Lenita Falck Moore1, Odd Kildahl-Andersen, Randi Kildahl-Andersen, Geir E Tjønnfjord.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23344600     DOI： 10.4045/tidsskr.12.0494

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN： 0029-2001


× No keyword cloud information.
  7 in total

Review 1.  Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia.

Authors:  David B Bregman; Lawrence T Goodnough
Journal:  Ther Adv Hematol       Date:  2014-04

2.  Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.

Authors:  Rebecca Frazier; Alexander Hodakowski; Xuan Cai; Jungwha Lee; Anaadriana Zakarija; Brady Stein; Valentin David; Myles Wolf; Tamara Isakova; Rupal Mehta
Journal:  Bone       Date:  2020-07-28       Impact factor: 4.398

3.  Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.

Authors:  Benedikt Schaefer; Philipp Würtinger; Armin Finkenstedt; Vickie Braithwaite; André Viveiros; Maria Effenberger; Irene Sulzbacher; Alexander Moschen; Andrea Griesmacher; Herbert Tilg; Wolfgang Vogel; Heinz Zoller
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 4.  Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review.

Authors:  John A Glaspy; Michelle Z Lim-Watson; Michael A Libre; Swagata S Karkare; Nandini Hadker; Aleksandra Bajic-Lucas; William E Strauss; Naomi V Dahl
Journal:  Ther Clin Risk Manag       Date:  2020-04-08       Impact factor: 2.423

5.  Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.

Authors:  Tatiane Vilaca; Nalini Velmurugan; Christopher Smith; Bo Abrahamsen; Richard Eastell
Journal:  J Bone Miner Res       Date:  2022-05-07       Impact factor: 6.390

Review 6.  Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.

Authors:  Philip A Kalra; Sunil Bhandari
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-03-10

7.  A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose.

Authors:  Giuseppe Rosano; Ingolf Schiefke; Udo-Michael Göhring; Vincent Fabien; Stefano Bonassi; Jürgen Stein
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.